Why carry out this study?

Anti-IL-17A trials for psoriasis, psoriatic arthritis, and spondyloarthritis have reported IBD events but no causative link or increased risk has been formally identified so far.

The study used a systematic review and meta-analysis methodology to try to determine if anti-IL-17 agents and anti-TNF agents were associated with inflammatory disease adverse events in those with psoriasis, spondylarthritis, and psoriatic arthritis.

What was learned from the study?

Pooled data from blinded RCTs of these three diseases finds IBD events to be very rare.

The low event rate of inflammatory bowel disease adverse events makes it challenging to determine whether there is a statistically significant increased rate.

Recognized methods of hypothesis testing these rare events have limitations and produce wide confidence intervals.